Lurasidone for the treatment of schizophrenia in adult and paediatric populations

Lurasidone for the treatment of schizophrenia in adult and paediatric populations

Schizophrenia is a common debilitating disorder characterized by significant impairments in how reality is perceived, combined with behavioural changes. In this review, we describe the lurasidone development programme for adult and paediatric patients. Both the pharmacokinetic and pharmacodynamic ch...

Full description

Bibliographic Details
Main Authors:	Teresa Guilera, Juan Pablo Chart Pascual, Maria del Carmen Blasco, Pilar Calvo Estopiñán, Rubén Asensio Piernas González, Isabel Ramírez Martínez, Cristóbal Rodríguez Moyano, Rita Prieto Pérez, Irene Gabarda-Inat, Juan L Prados-Ojeda, Marina Diaz-Marsà, Manuel Martín-Carrasco
Format:	Article
Language:	English
Published:	BioExcel Publishing Ltd 2023-02-01
Series:	Drugs in Context
Subjects:	case studies clinical trials lurasidone realworld data schizophrenia
Online Access:	https://www.drugsincontext.com/lurasidone-for-the-treatment-of-schizophrenia-in-adult-and-paediatric-populations/

Similar Items

Lurasidone-induced mania: A case report
by: T. Fernández, et al.
Published: (2022-06-01)

Treatment persistence in patients with schizophrenia treated with lurasidone in Italian clinical practice
by: Andrea Fagiolini, et al.
Published: (2022-12-01)

Cost analysis of lurasidone for the treatment of schizophrenia in adolescents and adults within the United Kingdom
by: Amy Dymond, et al.
Published: (2022-08-01)

Lurasidone treatment for delusional infestation in a patient with dementia
by: Yu-Ning Her, et al.
Published: (2023-01-01)

Real-world treatment patterns and outcomes in patients initiating lurasidone for the treatment of schizophrenia in Europe
by: A. Jones, et al.
Published: (2022-06-01)

Lurasidone for the Treatment of Schizophrenia: Design, Development, and Place in Therapy
by: Miura I, et al.
Published: (2023-09-01)

Lurasidone in adolescents with schizophrenia: Sustained remission and recovery during 2 years of open-label treatment
by: M. Tocco, et al.
Published: (2021-04-01)

Efficacy and safety of lurasidone in adolescents and young adults with schizophrenia: Pooled analysis of double-blind, placebo-controlled 6-week studies
by: F. Calisti, et al.
Published: (2021-04-01)

Lurasidone in treatment of manic episode
by: I. Sánchez-Rivero
Published: (2022-06-01)

Schizophrenia relapse, patient considerations, and potential role of lurasidone
by: Citrome L
Published: (2016-08-01)

Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China
by: Jia Liu, et al.
Published: (2022-09-01)

Lurasidone-induced tardive dyskinesia
by: Shreyas Shrikant Pendharkar, et al.
Published: (2022-01-01)

Corrigendum: Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China
by: Jia Liu, et al.
Published: (2022-11-01)

Clinical characteristics of lurasidone-treated patients in Spain using Natural Language Processing – A real-world data study with Electronic Health Records
by: C. De La Pinta, et al.
Published: (2022-06-01)

Practical Guidance on the Use of Lurasidone for the Treatment of Adults with Schizophrenia
by: Afzal Javed, et al.
Published: (2019-05-01)

The Role of Lurasidone in Managing Depressive Symptoms in People with Schizophrenia: A Review
by: Andrea Fiorillo, et al.
Published: (2024-02-01)

Efficacy and tolerability of lurasidone in schizophrenia: A systematic review and meta-analysis of short-term, randomized, placebo controlled trials
by: K. Hagi, et al.
Published: (2021-04-01)

Lurasidone treatment in a delusional disorder patient with atrial fibrillation: A case report
by: S. Marini, et al.
Published: (2021-04-01)

Risperidone-induced retrograde ejaculation and lurasidone may be the alternative
by: Natarajan Shanmugasundaram, et al.
Published: (2019-01-01)

Safety and Effectiveness of Lurasidone in Patients with Schizophrenia: A 12-Week, Open-Label Extension Study
by: Iyo M, et al.
Published: (2021-08-01)

Effects of Subchronic Administrations of Vortioxetine, Lurasidone, and Escitalopram on Thalamocortical Glutamatergic Transmission Associated with Serotonin 5-HT7 Receptor
by: Motohiro Okada, et al.
Published: (2021-01-01)

Lurasidone in the long-term treatment of Japanese patients with bipolar I disorder: a 52 week open label study
by: Teruhiko Higuchi, et al.
Published: (2021-08-01)

Augmentation strategy fluoxetine and lurasidone in the treatment of OCD with comorbid Restrictive Anorexia: a case report
by: L. Orsolini, et al.
Published: (2022-06-01)

Lurasidone versus Quetiapine for Cognitive Impairments in Young Patients with Bipolar Depression: A Randomized, Controlled Study
by: Xiangyuan Diao, et al.
Published: (2022-11-01)

Early onset tardive syndromes associated with Lurasidone in patients with mood disorders: A case series and literature review
by: Aditya Nidumolu, et al.
Published: (2022-12-01)

Effectiveness of Lurasidone 80 mg in Patients with Schizophrenia: Results of an Open-Label, 12-Week Extension Study
by: Miura I, et al.
Published: (2022-11-01)

Clinical Effectiveness of Lurasidone Monotherapy in Patients with Acute Episodes of Schizophrenia and Associated Symptoms of Depression
by: Alexander M. Reznik, et al.
Published: (2022-09-01)

Association of C-reactive protein and metabolic risk with cognitive effects of lurasidone in patients with schizophrenia
by: Brian J. Miller, et al.
Published: (2020-10-01)

A diagnostic test to examine early improvement as a predictor of later response to lurasidone in bipolar depression
by: Taro Kishi, et al.
Published: (2023-03-01)

Efficacy and safety of lurasidone in adolescents and young adults with schizophrenia: A pooled post hoc analysis of double-blind, placebo-controlled 6-week studies
by: Isabella Costamagna, et al.
Published: (2021-01-01)

The impacts of CYP3A4 genetic polymorphism and drug interactions on the metabolism of lurasidone
by: Qingqing Li, et al.
Published: (2023-12-01)

NRX-101 (D-cycloserine plus lurasidone) vs. lurasidone for the maintenance of initial stabilization after ketamine in patients with severe bipolar depression with acute suicidal ideation and behavior: a randomized prospective phase 2 trial
by: Andrew Nierenberg, et al.
Published: (2023-08-01)

Lurasidone Sub-Chronically Activates Serotonergic Transmission via Desensitization of 5-HT1A and 5-HT7 Receptors in Dorsal Raphe Nucleus
by: Motohiro Okada, et al.
Published: (2019-10-01)

Third-Generation Antipsychotics and Lurasidone in the Treatment of Substance-Induced Psychoses: A Narrative Review
by: Valerio Ricci, et al.
Published: (2024-01-01)

Short-term efficacy and safety of lurasidone versus placebo in antipsychotic-naïve versus previously treated adolescents with an acute exacerbation of schizophrenia
by: Christoph U. Correll, et al.
Published: (2022-01-01)

Long-Term Assessment of Lurasidone in Schizophrenia: Post Hoc Analysis of a 12-Month, Double Blind, Active-Controlled Trial and 6-Month Open-Label Extension Study
by: Preeya J. Patel, et al.
Published: (2020-10-01)

Improving Lurasidone Hydrochloride’s Solubility and Stability by Higher-Order Complex Formation with Hydroxypropyl-β-cyclodextrin
by: María Elena Gamboa-Arancibia, et al.
Published: (2023-01-01)

Tildrakizumab for the treatment of moderate-to-severe psoriasis: a 52-week, real-world Portuguese multicentric study
by: Tiago Torres, et al.
Published: (2024-03-01)

The Novel Atypical Antipsychotic Lurasidone Affects Cytochrome P450 Expression in the Liver and Peripheral Blood Lymphocytes
by: Przemysław J. Danek, et al.
Published: (2023-11-01)

Weight changes before and after lurasidone treatment: a real-world analysis using electronic health records
by: Jonathan M. Meyer, et al.
Published: (2017-10-01)